Prescribing Information Including Boxed
Found 9 free book(s)
HIGHLIGHTS OF PRESCRIBING INFORMATION CAR-positive …
www.novartis.usSee full prescribing information for complete boxed warning. • Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving KYMRIAH. Do not administer KYMRIAH to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with
HIGHLIGHTS OF PRESCRIBING INFORMATION BOTOX
media.allergan.comSee full prescribing information for complete boxed warning. The effects of BOTOXand all botulinum toxin products may spread from ... BOTOX is indicated for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and older.
HIGHLIGHTS OF PRESCRIBING INFORMATION • Inject ...
www.novo-pi.comSee full prescribing information for complete boxed warning. • In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY™ causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid
DOSAGE FORMS AND STRENGTHS See full prescribing ...
www.austedo.comSee full prescribing information for complete boxed warning. ... VMAT2 inhibitors, including AUSTEDO, may cause a worsening in mood, cognition, rigidity, and functional capacity. Prescribers should periodically re-evaluate the need for AUSTEDO in their patients by assessing
Prophylaxis of DVT following hip or knee replacement ...
packageinserts.bms.comSee full prescribing information for complete boxed warning. (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS: Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if …
Prescribing Information | OPZELURA™ (ruxolitinib)
www.opzelura.comSee full prescribing information for complete boxed warning. • • Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving Janus kinase inhibitors for inflammatory conditions. (5.1)
HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE …
seagendocs.comaccordingly (5.1).See full prescribing information for complete boxed warning. † Anaphylaxis and infusion reactions: If an infusion reaction occurs, interrupt the infusion. If anaphylaxis occurs, immediately discontinue the infusion (5.2). † Hematologic toxicities: Monitor complete blood counts. Monitor for signs of infection.
DOSAGE AND ADMINISTRATION HIGHLIGHTS OF …
solirispro.comSee full prescribing information for complete boxed warning Life-threatening and fatal meningococcal infections have occurred in patients treated with Soliris and may become rapidly life-threatening or fatal if not recognized and treated early (5.1). outweigh the
Prescribing Information | SUBLOCADE® (buprenorphine ...
www.sublocade.comSee full prescribing information for SUBLOCADE. SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use, CIII Initial U.S. Approval: 2002 WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY See full prescribing information for complete …